Jefferies assumed coverage of Novo Nordisk (NVO) with an Underperform rating and DKK 290 price target Obesity growth dynamics seem to be softening, Novo is over-indexed to semaglutide and “there appears to be no real manufacturing moat anymore,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk backed MapLight raises $258.9M in IPO, Bloomberg says
- Mixed options sentiment in Novo Nordisk with shares down 0.59%
- Novo Nordisk Shares (NVO) Slip after Largest Shareholder Proposes Major Board Shake-Up
- Midday Fly By: Netflix, TI reports weigh on markets
- Mixed options sentiment in Novo Nordisk with shares down 2.58%